Synaptogenix Inc (SNPX)

[Cyosol]

That sure is some wonky data.

All I can read from this is that the drug is useless in severe patients and slightly better than placebo in moderate patients on average, but the huge standard deviations mean that patients in both cohorts are all over the place. Some placebo patients in the severe cohort improved by as much as 16 points.

At least the average improvement in moderate patients seems to be stable across trials at around 4+ SIB points. Maybe the next trial will shed some more light on this, but I have a feeling we won't get a satisfying answer until phase 3 results are out.